Roche’s Itovebi™ (inavolisib) significantly improved overall survival in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer patients, according to final Phase III INAVO120 trial results.
Breast Cancer
The creation of these implants is a direct answer to the demands of patients who need primary or revision reconstruction following a mastectomy.
The combination immunotherapy affected distant metastases in addition to the treated tumors. It increased the sensitivity of melanomas to checkpoint inhibitors and decreased the creation of new metastases, hence reducing malignant relapses.
Teri Boudreaux is thankful for the time she gets to spend with her family, whether it’s hiking, playing with her grandkids, travelling with her spouse, lounging on the beach, or taking up new interests like pickleball. She has survived breast cancer twice. In spite of everything, though, she still harbours […]
